FDA Adverse Event Malfunction Summary report: N

OPTIFLOW JUNIOR INTERFACE

MDR report key: 3010390 · Received March 19, 2013

Report

Report Number
9611451-2013-00199
Event Type
Malfunction
Date Received
March 19, 2013
Date of Event
February 18, 2013
Report Date
February 18, 2013
Manufacturer
FISHER & PAYKEL HEALTHCARE LTD
Product Code
CAT
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
NM, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). METHOD: FISHER & PAYKEL DID NOT RECEIVE THE COMPLAINT CANNULA. WE WERE INFORMED THAT THE COMPLAINT DEVICE WAS NOT AVAILABLE FOR EVALUATION. RESULTS: A LOT CHECK REVEALED NO OTHER COMPLAINTS FOR LOT 121026. CONCLUSION: WITHOUT THE COMPLAINT DEVICE WE WERE UNABLE TO CONFIRM WHAT HAD CAUSED THE PROBLEM AS REPORTED BY THE HOSPITAL. THE OPTIFLOW JUNIOR CANNULA IS DESIGNED SPECIFICALLY FOR THE DELICATE ANATOMICAL FEATURES AND FLOW REQUIREMENTS OF NEONATAL AND PAEDIATRIC PATIENTS. IT FEATURES ADHESIVE PADS TO MAINTAIN CANNULA STABILITY ON THE PATIENT'S CHEEKS, SOFT-TOUCH NASAL PRONGS AND BREATHABLE KINK-PROOF AND CRUSH-RESISTANT FLEXIBLE TUBING. THE OPTIFLOW JUNIOR PROVIDES A REVOLUTIONARY STEP BETWEEN LOW-FLOW OXYGEN THERAPY AND CPAP. OUR USER INSTRUCTIONS THAT ACCOMPANY THE OPT316 CANNULA STATE: UNDER EXCESSIVE LOAD, THE CANNULA MAY DISCONNECT TO PREVENT FORCES BEING TRANSFERRED TO THE PATIENT. ENSURE THAT ALL CONNECTIONS ARE SECURE DURING USE PATIENT MONITORING IS RECOMMENDED. FISHER & PAYKEL HEALTHCARE MAINTAINS A CLOSE SUPERVISION OF THIS PRODUCT AND ITS BEHAVIOUR IN THE FIELD IN ORDER TO GAIN INFORMATION. WE ARE CONTINUOUSLY WORKING TO IMPROVE THE OPT318 BASED ON CUSTOMER FEEDBACK.

Description of Event or Problem · 1

A HOSPITAL IN (B)(6) REPORTED VIA OUR DISTRIBUTOR THAT AN OPT318 OPTIFLOW JUNIOR NASAL CANNULA WAS PULLED APART BY A (B)(6). NO PATIENT CONSEQUENCE WAS REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
113948 OPTIFLOW JUNIOR INTERFACE CAT CAT FISHER & PAYKEL HEALTHCARE LTD OPT318 121026

Patients

Seq Age Sex Outcome Treatment
1